Novartis (Singapore)

Recent papers from Novartis (Singapore)

1. Optimize reliance pathways to advance patient’s access through good regulatory practice: recommendations from the Asia Partnership Conference of Pharmaceutical Associations (APAC)AAPS Open · 2026
2. Real-world assessment of low-density lipoprotein cholesterol goal, disease burden and financial burden among patients with atherosclerotic cardiovascular disease in Singapore—A single-centre retrospective cohort studyFrontiers in Cardiovascular Medicine · 2026
3. Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness StudyPharmacoEconomics - Open · 2026
4. A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancerTherapeutic Advances in Medical Oncology · 2025
5. Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study)BMJ Open Ophthalmology · 2025
6. Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet NeedsHematological Oncology · 2025
7. Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in SingaporeFrontiers in Cardiovascular Medicine · 2025
8. Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in SingaporeValue in Health Regional Issues · 2025
9. Advancements in regulatory agility, regional collaboration, and digital transformation: insights from the Asia Partnership Conference of Pharmaceutical Associations (APAC)AAPS Open · 2024
10. Examining the mediating role of organizational pride on the relationship of human values and work outcomes of facilities managersFacilities · 2024
11. Turning the Page on Hardcopy Risk Management Plan Educational Materials: Digitalization Made PossibleTherapeutic Innovation & Regulatory Science · 2024
12. A Global Industry Survey on Post-Approval Change Management and Use of RelianceTherapeutic Innovation & Regulatory Science · 2024
13. Atherosclerotic cardiovascular disease landscape in SingaporeFrontiers in Cardiovascular Medicine · 2024
14. Lipoprotein(a) distribution in hospitalised Asian patients with ischaemic heart diseaseTherapeutic Advances in Cardiovascular Disease · 2024
15. Dual pH and ultrasound responsive curcumin loaded g-C 3 N 4 /Ba(OH) 2 nanocarrier for chemo-photodynamic therapyNew Journal of Chemistry · 2024
16. Imidazolopiperazine (IPZ)-Induced Differential Transcriptomic Responses on Plasmodium falciparum Wild-Type and IPZ-Resistant Mutant ParasitesGenes · 2023
17. A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studiesGene Therapy · 2023
18. Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infectionsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2023
19. A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in SingaporeCost Effectiveness and Resource Allocation · 2023
20. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature ReviewClinical ophthalmology · 2022